Portal Hypertension Diagnosis and Management

Definition and Pathophysiology

Portal hypertension is defined as a pathological increase in portal pressure with a hepatic venous pressure gradient (HVPG) above 5 mmHg, with clinically significant portal hypertension (CSPH) occurring at HVPG ≥10 mmHg, as stated by the American Association for the Study of Liver Diseases 1, 2
Portal hypertension develops through a combination of increased intrahepatic resistance and increased portal blood flow, following the hydraulic equivalent of Ohm's law where "Pressure = Resistance × Flow" 1, 3
The increased intrahepatic resistance has two components: a structural component (70%) due to fibrous tissue, vascular distortion from regenerative nodules, and microthrombi, and a functional component (30%) due to endothelial dysfunction resulting from reduced nitric oxide bioavailability 3

The gold standard for diagnosing and quantifying portal hypertension is measurement of the hepatic venous pressure gradient (HVPG) 1, 4
Normal HVPG: 1-5 mmHg, portal hypertension: HVPG >5 mmHg, and clinically significant portal hypertension (CSPH): HVPG ≥10 mmHg 1
Non-invasive assessment methods include imaging-based tests such as transient elastography (TE) with sensitivity 90-96% and specificity 48-50% at 15 kPa, and blood-based tests like APRI with 56% sensitivity and 68% specificity 4
First-line investigation for extrahepatic portal vein obstruction is Doppler ultrasound, with CT for confirmation, as recommended by the European Association for the Study of the Liver 5, 6

HVPG ≥10 mmHg is associated with higher risk of clinical decompensation, and HVPG ≥16 mmHg is strongly associated with increased mortality, according to the American Association for the Study of Liver Diseases 1, 4
In compensated cirrhosis, HVPG reduction of ≥10% after therapy is associated with decreased risk of first variceal hemorrhage 4

Treatment strategy depends on the stage of portal hypertension, with mild portal hypertension (HVPG >5 but <10 mmHg) focusing on treating the underlying cause, and CSPH without varices (HVPG ≥10 mmHg) focusing on preventing clinical decompensation, as stated by the American Association for the Study of Liver Diseases 1, 2
For variceal bleeding, acute management includes vasoactive agents and endoscopic therapy, as recommended by the American College of Gastroenterology 2
For ascites, survival decreases from 80% at 5 years in compensated cirrhosis to 50% when ascites develops, and liver transplantation should be considered for all patients with decompensated cirrhosis, according to the American Association for the Study of Liver Diseases 2

Screening for extrahepatic portal vein obstruction should be considered in patients with myeloproliferative disease and antiphospholipid syndrome, as recommended by the European Association for the Study of the Liver 5, 6
Idiopathic non-cirrhotic portal hypertension (INCPH) should be diagnosed only after excluding other causes of portal hypertension, and in patients with extrahepatic portal vein obstruction, once prophylaxis for gastrointestinal bleeding has been implemented, treat underlying prothrombotic conditions, according to the European Association for the Study of the Liver 5, 6

Activated hepatic stellate cells alter sinusoidal blood flow after activation, contributing significantly to increased intrahepatic resistance 7
Increased portal blood flow occurs as the disease progresses, with splanchnic vasodilation contributing to elevated portal pressure 7

Chronic viral hepatitis B/C is a common cause of portal hypertension, accounting for a significant proportion of cases, according to the European Association for the Study of the Liver 8
Non-alcoholic steatohepatitis is a common cause of portal hypertension, as stated by the American Association for the Study of Liver Diseases 8
Idiopathic non-cirrhotic portal hypertension (INCPH) is characterized by portal hypertension with patent portal/hepatic veins but without cirrhosis on biopsy, as described by the European Association for the Study of the Liver 8

Transient elastography (liver stiffness measurement) is a non-invasive alternative for diagnosing portal hypertension, with a sensitivity of 90-96% and specificity of 48-50% at 15 kPa cutoff, as recommended by the American Association for the Study of Liver Diseases 7
Patients with INCPH are often radiologically misclassified as cirrhotic, but a clue for INCPH is low liver stiffness (<12 kPa) despite signs of portal hypertension, as noted by the European Association for the Study of the Liver 8

HVPG ≥10 mmHg predicts higher risk of clinical decompensation in compensated cirrhosis, as stated by the American Association for the Study of Liver Diseases 7
HVPG ≥16 mmHg is strongly associated with increased mortality, according to the European Association for the Study of the Liver 7

Splenomegaly/hypersplenism is a common presentation in compensated cirrhosis, as described by the European Association for the Study of the Liver 8
Incidental finding of varices on screening is a common presentation in compensated cirrhosis, as noted by the American Association for the Study of Liver Diseases 8